India Pharma Outlook Team | Tuesday, 08 September 2026
Obesity drug market swings between big wins and bigger doubts as the latest updates reveal both striking advances and stubborn limits.
Patients, doctors and investors watch every trial result and sales figure. These GLP-1 medicines reshape diabetes care, reduce cardiovascular risk for millions, and drive enormous revenue for companies.
The urgency grows clearer every month: childhood obesity rates climb, emerging markets surge in demand, and many adults still struggle with weight that no current injection fully controls. Understanding the latest shifts helps to decide how far these drugs can truly go.
Novo Nordisk ended two additional studies of ziltivekimab in heart-failure patients ahead of schedule. A company spokesperson told Reuters that the data-monitoring committee found a low likelihood of different results from an earlier failed trial that tested the same drug against major cardiovascular events.
One remaining trial in patients recovering from heart attack will continue, with results due in the first half of 2027. These decisions further dim Novo’s efforts to expand beyond its dominant obesity and diabetes franchise and add pressure after a similar failure by a Novartis heart drug earlier the same week.
Also Read: GLP-1 Side Effects: Tips for Gastrointestinal Comfort 2026 Update
In the STEP Young trial, children who received once-weekly semaglutide plus lifestyle changes achieved superior body-mass-index reduction compared with placebo at week 68. Novo reported that 40.4 percent of those treated no longer met the clinical definition of obesity when researchers assumed full adherence.
Safety matched the profile already seen in adults and adolescents. Chief Scientific Officer Martin Holst Lange called the results encouraging for children who need medical treatment alongside diet and activity changes.
The data arrive as prescriptions for GLP-1 drugs among U.S. children under 12 have already risen more than 300-fold since 2019, even without formal approval for that age group.
Mounjaro, containing tirzepatide, recorded Rs 1,256 crore in sales and overtook every other pharmaceutical brand in India for the year ending August 2026, The Hindu Business Line reported, citing Pharmatrac data.
Sales jumped 502 percent year-on-year. Tirzepatide now holds roughly three-quarters of the injectable GLP-1 drug market by value and 62 percent of the overall GLP-1 market.
India’s total GLP-1 market has grown almost 15-fold since August 2022 to Rs 2,333 crore. Doctors note that weekly injections offer stronger metabolic benefits and greater convenience than oral options, driving the sharp patient shift.
Not every patient benefits; clinical trials show that between 9 percent and one-third of participants lose less than 5 percent of body weight, depending on the drug and dose, The Guardian reported. Patients describe persistent food cravings that feel like heroin withdrawal and express deep disappointment after months of treatment.
Researchers point to possible roles for age, sex, diabetes status, ancestry, hormones and specific genetic variants, yet they still cannot reliably predict who will respond. Experts stress that non-response is neither the patient’s nor the drug’s fault; it simply reflects biological variation that future medicines must address.
Together, these developments show an obesity drug market that expands rapidly into new ages and geographies while simultaneously confronting pipeline failures and incomplete efficacy. The next wave of treatments will need to close the gaps that today’s big wins still leave open.
.jpg)
